Christopher Ryan Sullivan
Purchase track record
Not enough history. Based on 0 purchases with a full 90 days of price history.
—
Avg. 90-day return—
vs. S&P 500—
Beat the market—
Paper profit on buys$0
Total bought / sold$0 / $3.7M
Reported trades
| Filed | Stock | Type | Shares | Price | Value | Since |
|---|---|---|---|---|---|---|
| Sep 18SEC | AVTXAvalo Therapeutics, Inc. | Sell Plan | 12,39439,900 held (−24%) | $16.33 | $202K | -16.4% |
| Sep 11SEC | AVTXAvalo Therapeutics, Inc. | Sell Plan | 10,18539,900 held (−20%) | $17.62 | $179K | -22.5% |
| Aug 19SEC | AVTXAvalo Therapeutics, Inc. | Sell Plan | 37,94543,649 held (−47%) | $19.85 | $753K | -31.2% |
| Aug 19SEC | AVTXAvalo Therapeutics, Inc. | Sell Plan | 3,74939,900 held (−9%) | $19.94 | $75K | -31.5% |
| Aug 19SEC | AVTXAvalo Therapeutics, Inc. | Sell Plan | 31,03139,900 held (−44%) | $20.05 | $622K | -31.9% |
| May 11SEC | AVTXAvalo Therapeutics, Inc. | Sell Plan | 18,606423 held (−98%) | $24.12 | $449K | -43.4% |
| May 7SEC | AVTXAvalo Therapeutics, Inc. | Sell Plan | 13,83433,589 held (−29%) | $18.55 | $257K | -26.4% |
| May 7SEC | AVTXAvalo Therapeutics, Inc. | Sell Plan | 12,34721,242 held (−37%) | $19.28 | $238K | -29.2% |
| May 7SEC | AVTXAvalo Therapeutics, Inc. | Sell Plan | 2,70018,542 held (−13%) | $20.76 | $56K | -34.2% |
| May 7SEC | AVTXAvalo Therapeutics, Inc. | Sell Plan | 9,2199,323 held (−50%) | $21.37 | $197K | -36.1% |
| May 7SEC | AVTXAvalo Therapeutics, Inc. | Sell Plan | 8,900423 held (−95%) | $22.57 | $201K | -39.5% |
| May 1SEC | AVTXAvalo Therapeutics, Inc. | Sell Plan | 8,4588,880 held (−49%) | $13.09 | $111K | +4.3% |
| May 1SEC | AVTXAvalo Therapeutics, Inc. | Sell Plan | 8,457423 held (−95%) | $13.23 | $112K | +3.2% |
| Apr 3SEC | AVTXAvalo Therapeutics, Inc. | Sell Plan | 50032,797 held (−2%) | $15.86 | $8K | -13.9% |
| Apr 3SEC | AVTXAvalo Therapeutics, Inc. | Sell Plan | 7,47925,318 held (−23%) | $16.83 | $126K | -18.9% |
| Apr 3SEC | AVTXAvalo Therapeutics, Inc. | Sell Plan | 6,20019,118 held (−24%) | $17.02 | $106K | -19.8% |
| Apr 3SEC | AVTXAvalo Therapeutics, Inc. | Sell Plan | 1,78017,338 held (−9%) | $17.57 | $31K | -22.3% |
- Sell
CFO Christopher Ryan Sullivan sold $202K of AVTX at $16.33 — pre-scheduled 10b5-1 plan sale.
- Sell
CFO Christopher Ryan Sullivan sold $179K of AVTX at $17.62 — pre-scheduled 10b5-1 plan sale.
- Sell
CFO Christopher Ryan Sullivan sold $753K of AVTX at $19.85 — cuts the stake by 47%; pre-scheduled 10b5-1 plan sale.
- Sell
CFO Christopher Ryan Sullivan sold $75K of AVTX at $19.94 — pre-scheduled 10b5-1 plan sale.
- Sell
CFO Christopher Ryan Sullivan sold $622K of AVTX at $20.05 — cuts the stake by 44%; pre-scheduled 10b5-1 plan sale.
- Sell
CFO Christopher Ryan Sullivan sold $449K of AVTX at $24.12 — cuts the stake by 98%; pre-scheduled 10b5-1 plan sale.